TRIAL INFORMATION
Sponsor:NeuroScience Global
Therapeutic Area:Neurology
Phase:PHASE II
Indication:Multiple Sclerosis (Relapsing-Remitting)
Target Enrollment:30 patients
Est. Duration:32 months
SITE INFORMATION
Site:MedPoint Clinical Research - Nashville
Principal Investigator:Dr. Sarah Chen, MD, PhD
Total FTE Capacity:12
Available FTE:1.8
Active Trials:6
Completed Trials:18
Pool Analysis
FTE Analysis
Financial
Risk Assessment
Recommendation
Patient Pool Adequacy Analysis
Assessing whether the available patient pool can support target enrollment
TOTAL POOL
1,800
AVAILABLE
1,480
320 allocated
REQUIRED
30
ADEQUACY RATIO
49.3x
Pool Utilization
Current Allocation17.8%
If This Trial Accepted19.4%
Pool is Sufficient
Available pool is 49.3x the target enrollment, providing a comfortable buffer for recruitment.
Pool Adequacy Score100 / 100